Immuno-oncology
Home / Our therapy areas / Oncology / Immuno-oncology
Harnessing the power of the immune system
澳门第一赌城在线娱乐的免疫系统有天然的监视机制来评估或消除对澳门第一赌城在线娱乐健康的潜在威胁.1,2 The system works well, 但流氓细胞有时会溜过这些监视机制，变成癌症.3 By providing the immune system with tools for recognising tumours, 免疫肿瘤学治疗可以识别和响应澳门第一赌城在线娱乐的先天免疫监视机制可能错过的癌症的存在.1,4
免疫肿瘤学在癌症的靶向治疗方面取得了成功，但是 recent advances 澳门第一赌城在线娱乐对免疫系统的理解正在为下一波疗法的发展提供信息，这些疗法有可能对所有疾病阶段的患者产生更大的影响.
At AstraZeneca, 澳门第一赌城在线娱乐正在不断突破科学的界限，坚持不懈地致力于利用免疫系统来重新构想癌症治疗，并帮助患者改变治疗结果.
Going bold – addressing areas of high unmet need
澳门第一赌城在线娱乐有大胆探索新的免疫肿瘤治疗方法的历史. 澳门第一赌城在线娱乐不断挑战现状，专注于在免疫肿瘤学可能产生最大影响的领域为未满足需求的患者提供新的治疗选择, including many cancers with particularly difficult biology. 澳门第一赌城在线娱乐的目标是将新的基于免疫肿瘤学的治疗方法应用到胃肠道的新环境中, genitourinary, lung and gynaecological cancers.
We pursue this ambition without fear of failure, 从每一项临床试验中获得关键知识，进一步提高澳门第一赌城在线娱乐对难治性疾病的理解，有可能使更广泛的患者受益.
Moving early – committing to earlier diagnosis and treatment
We believe treating cancer earlier, 澳门第一赌城在线娱乐如何利用免疫系统来识别和根除癌细胞, 是否有最大的机会最大化长期缓解的潜力和治愈的可能性.5-7 While metastatic disease has long been an area of focus in cancer research, 澳门第一赌城在线娱乐 意识到在疾病早期治疗癌症的潜力，并将免疫肿瘤学治疗转移到新辅助(手术前)和辅助(手术后)环境中.
Today, we are a leader in this space, 澳门第一赌城在线娱乐超过三分之二的三期试验是在早期癌症阶段. 澳门第一赌城在线娱乐广泛的早期疾病规划为各种癌症提供了新的和必要的治疗方案.
It is our hope that the earlier we can detect and treat cancer, the closer we are to potentially helping more patients live longer lives. That is why we’re utilising smart screening tools, 探索新的终点并建立战略合作伙伴关系，以加速早期免疫肿瘤学方案，澳门第一赌城在线娱乐相信这些方案将继续在癌症治疗革命中发挥关键作用.
Innovate – exploring next-generation combination treatment strategies
创新是澳门第一赌城在线娱乐临床战略的核心，澳门第一赌城在线娱乐专注于探索新的免疫肿瘤学组合，为更多的患者带来希望，并改变患者的预后.
澳门第一赌城在线娱乐有多种多样的免疫肿瘤学分子和潜在药物组合，澳门第一赌城在线娱乐正在不断研究新的机制, including bispecific antibodies, novel checkpoint inhibitors, T cell engagers, and cell therapies, to help drive more sustained immune responses. 澳门第一赌城在线娱乐的免疫肿瘤学资产正在与各种形式的组合进行评估, both within and outside our portfolio, 包括与抗体药物偶联物的联合，澳门第一赌城在线娱乐相信这可能有潜力取代免疫肿瘤学方案中的传统化疗.
In addition, 澳门第一赌城在线娱乐正在研究创新的免疫肿瘤学组合和独特的给药策略，以改变晚期疾病的护理标准，并帮助患者提供具有临床意义和持续的反应.
We are balancing our focus on our pipeline with the active management of our existing medicines; expanding indications and exploring novel treatment combinations to deliver to those patients with the greatest unmet need. Our goal is to drive long-term survivorship across multiple tumour types, stages of disease and lines of treatment, with the potential to change what it means to live with cancer.
In the spotlight
Join AstraZeneca
We are driven by our passion, our people and a culture of innovation. We value courage, curiosity, collaboration and passion for learning, 澳门第一赌城在线娱乐鼓励颠覆性思维，在这种思维中，失败是一个学习的机会——可以自由地承担风险，而不必担心失败.
References
1. Melero I, et al. 免疫刺激单克隆抗体的临床发展及联合应用的机会. Clin Cancer Res. 2013;19(5):997-1008.
2. Finn O. 免疫肿瘤学:了解免疫系统在癌症中的功能和功能障碍. Ann Oncol. 2012;23(Suppl_8):viii6-viii9.
3. Beatty, GL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692.
4. Eggermont A, et al. Advances in immuno-oncology. Ann Oncol. 2012;23(Suppl_8 Foreword):viii5.
5. Cancer Research UK. The immune system and cancer. Available at: http://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-immune-system-and-cancer. Accessed October 2022.
6. Hawkes N. Cancer survival data emphasise importance of early diagnosis. BMJ. 2019;364:1408. Accessed October 2022.
7. American Cancer Society. Why People with Cancer Are More Likely to Get Infections. Available at: http://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html. Accessed October 2022.
Veeva ID: Z4-49847
Date of preparation: October 2022
Veeva ID: Z4-48196
Date of preparation: October 2022